Clinical Trials
3 trialsNCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05682170 2024-09-19
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT06055348 2023-09-26
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown